Cargando…

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination

BACKGROUND: Merkel cell carcinoma (MCC) is a rare but very aggressive skin tumor that develops after integration of a truncated form of the large T-antigen (truncLT) of the Merkel cell polyomavirus (MCV) into the host’s genome. Therapeutic vaccination with dendritic cells (DCs) loaded with tumor ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerer, Kerstin F., Erdmann, Michael, Hadrup, Sine R., Lyngaa, Rikke, Martin, Lena-Marie, Voll, Reinhard E., Schuler-Thurner, Beatrice, Schuler, Gerold, Schaft, Niels, Hoyer, Stefanie, Dörrie, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502952/
https://www.ncbi.nlm.nih.gov/pubmed/28717398
http://dx.doi.org/10.1177/1758834017712630
_version_ 1783249012794589184
author Gerer, Kerstin F.
Erdmann, Michael
Hadrup, Sine R.
Lyngaa, Rikke
Martin, Lena-Marie
Voll, Reinhard E.
Schuler-Thurner, Beatrice
Schuler, Gerold
Schaft, Niels
Hoyer, Stefanie
Dörrie, Jan
author_facet Gerer, Kerstin F.
Erdmann, Michael
Hadrup, Sine R.
Lyngaa, Rikke
Martin, Lena-Marie
Voll, Reinhard E.
Schuler-Thurner, Beatrice
Schuler, Gerold
Schaft, Niels
Hoyer, Stefanie
Dörrie, Jan
author_sort Gerer, Kerstin F.
collection PubMed
description BACKGROUND: Merkel cell carcinoma (MCC) is a rare but very aggressive skin tumor that develops after integration of a truncated form of the large T-antigen (truncLT) of the Merkel cell polyomavirus (MCV) into the host’s genome. Therapeutic vaccination with dendritic cells (DCs) loaded with tumor antigens is an active form of immunotherapy, which intends to direct the immune system towards tumors which express the respective vaccination antigens. METHODS: Cytokine-matured monocyte-derived DCs of healthy donors and MCC patients were electroporated with mRNA encoding the truncLT. To permit major histocompatibility complex (MHC) class II next to class I presentation, we used an RNA construct in which the antigen was fused to a DCLamp sequence in addition to the unmodified antigen. To further improve their immunogenicity, the DCs were additionally activated by co-transfection with the constitutively active nuclear factor (NF)-κB activator caIKK. These DCs were used to stimulate autologous CD8(+) T-cells or a mixture of CD4(+) and CD8(+) T-cells. Then the percentage of T-cells, specific for the truncLT, was quantified by interferon (IFN)γ ELISpot assays. RESULTS: Both the truncLT and its DCLamp-fusion were detected within the DCs by flow cytometry, albeit the latter required blocking of the proteasome. The transfection with caIKK upregulated maturation markers and induced cytokine production. After 2–3 rounds of stimulation, the T-cells from 11 out of 13 healthy donors recognized the antigen. DCs without caIKK appeared in comparison less potent in inducing such responses. When using cells derived from MCC patients, we could induce responses for 3 out of 5 patients; however, here the caIKK-transfected DCs did not display their superiority. CONCLUSION: These results show that optimized DCs are able to induce MCV-antigen-specific T-cell responses. Therapeutic vaccination with such transfected DCs could direct the immune system against MCC.
format Online
Article
Text
id pubmed-5502952
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55029522017-07-17 Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination Gerer, Kerstin F. Erdmann, Michael Hadrup, Sine R. Lyngaa, Rikke Martin, Lena-Marie Voll, Reinhard E. Schuler-Thurner, Beatrice Schuler, Gerold Schaft, Niels Hoyer, Stefanie Dörrie, Jan Ther Adv Med Oncol Original Research BACKGROUND: Merkel cell carcinoma (MCC) is a rare but very aggressive skin tumor that develops after integration of a truncated form of the large T-antigen (truncLT) of the Merkel cell polyomavirus (MCV) into the host’s genome. Therapeutic vaccination with dendritic cells (DCs) loaded with tumor antigens is an active form of immunotherapy, which intends to direct the immune system towards tumors which express the respective vaccination antigens. METHODS: Cytokine-matured monocyte-derived DCs of healthy donors and MCC patients were electroporated with mRNA encoding the truncLT. To permit major histocompatibility complex (MHC) class II next to class I presentation, we used an RNA construct in which the antigen was fused to a DCLamp sequence in addition to the unmodified antigen. To further improve their immunogenicity, the DCs were additionally activated by co-transfection with the constitutively active nuclear factor (NF)-κB activator caIKK. These DCs were used to stimulate autologous CD8(+) T-cells or a mixture of CD4(+) and CD8(+) T-cells. Then the percentage of T-cells, specific for the truncLT, was quantified by interferon (IFN)γ ELISpot assays. RESULTS: Both the truncLT and its DCLamp-fusion were detected within the DCs by flow cytometry, albeit the latter required blocking of the proteasome. The transfection with caIKK upregulated maturation markers and induced cytokine production. After 2–3 rounds of stimulation, the T-cells from 11 out of 13 healthy donors recognized the antigen. DCs without caIKK appeared in comparison less potent in inducing such responses. When using cells derived from MCC patients, we could induce responses for 3 out of 5 patients; however, here the caIKK-transfected DCs did not display their superiority. CONCLUSION: These results show that optimized DCs are able to induce MCV-antigen-specific T-cell responses. Therapeutic vaccination with such transfected DCs could direct the immune system against MCC. SAGE Publications 2017-06-13 2017-07 /pmc/articles/PMC5502952/ /pubmed/28717398 http://dx.doi.org/10.1177/1758834017712630 Text en © The Author(s), 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Gerer, Kerstin F.
Erdmann, Michael
Hadrup, Sine R.
Lyngaa, Rikke
Martin, Lena-Marie
Voll, Reinhard E.
Schuler-Thurner, Beatrice
Schuler, Gerold
Schaft, Niels
Hoyer, Stefanie
Dörrie, Jan
Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
title Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
title_full Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
title_fullStr Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
title_full_unstemmed Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
title_short Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
title_sort preclinical evaluation of nf-κb-triggered dendritic cells expressing the viral oncogenic driver of merkel cell carcinoma for therapeutic vaccination
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502952/
https://www.ncbi.nlm.nih.gov/pubmed/28717398
http://dx.doi.org/10.1177/1758834017712630
work_keys_str_mv AT gererkerstinf preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT erdmannmichael preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT hadrupsiner preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT lyngaarikke preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT martinlenamarie preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT vollreinharde preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT schulerthurnerbeatrice preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT schulergerold preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT schaftniels preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT hoyerstefanie preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination
AT dorriejan preclinicalevaluationofnfkbtriggereddendriticcellsexpressingtheviraloncogenicdriverofmerkelcellcarcinomafortherapeuticvaccination